Skip to content
Fitness-and-exercise — Probably — Headquarters — Nature — Decode — Dismissal — News — Geneticist — health-and-wellness — Science

Stefanson Speaks about Sudden Dismissal with Optimism: "I Feel Fulfilled and Content Now"

Geneticist Kári Stefánsson, founder of deCode Genetics, expresses expectation over his unexpected termination from the firm he headed for almost three decades. In an interview with mbl.is, Stefánsson attributes the sudden change in his position to conflicting scientific objectives between...

,   and  Administrator
3 min read
Geneticist Kári Stefánsson, founder of deCode Genetics and a renowned figure in the field, was...
Geneticist Kári Stefánsson, founder of deCode Genetics and a renowned figure in the field, was unphased by his unexpected exit from the company he helmed for nearly three decades. In an interview with mbl.is, Stefánsson attributed his departure to diverging scientific objectives between him and deCode's parent company, Amgen, stating it as a predictable outcome.

Stefanson Speaks about Sudden Dismissal with Optimism: "I Feel Fulfilled and Content Now"

Sparking Change in the Genetic World: Kári Stefánsson's Unexpected Departure from deCode Genetics

Kári Stefánsson, the globe-trotting geneticist renowned as the world's most prolific geneticist, didn't flinch when the axe fell on May 1st, Labor Day. Speaking candidly to mbl.is, Stefánsson perceived his abrupt exit as a natural consequence of clashing scientific priorities between himself and Amgen, deCode's parent company.

The Californian Showdown

The fateful encounter unfolded at Amgen headquarters in Thousand Oaks, California. Stefánsson had been under the impression that the meeting was to discuss a potential collaboration with Abu Dhabi. Instead, he was taken aback when informed that his tenure with deCode had reached its end. Meanwhile, his loyal comrades Patrick Sulem and Daníel Guðbjartsson were discreetly removed from the gathering and whisked back to Iceland by private jet.

Clashing Perspectives

In hindsight, Stefánsson attributes the decision to a fundamental divergence in philosophy: Amgen's emphasis on targeted drug development, versus his own passion for broad, integrative research. "I'm a bit of a science groupie, always searching for the secrets between the stars and the earth," he mused.

Bitter? Not Kári Stefánsson. "I'm a satisfied old man now," he declared. With two books on his plate and a spark still igniting in his scientific curiosity, Stefánsson is open to rekindling his work in genetics elsewhere.

Unshaken Legacy

Stefánsson's departure marks a turning point, but his impact remains indelible. Through deCode's groundbreaking work, Iceland shot to the forefront of global genetic research. Even as he steps down, Stefánsson's insatiable scientific curiosity persists.

As Amgen and Stefánsson symbolize distinct but interconnected approaches to biomedical science, their differing priorities and strategies demonstrate the breadth and depth of scientific progress. Amgen's mission lies in transforming scientific breakthroughs into patient-focused therapies, while Stefánsson pursues comprehensive genetic and epidemiological analysis to illuminate the genetic foundations of disease and drive personalized medicine and drug discovery. The two methodologies complement each other, forging ahead in the echoing halls of the genetic realm.

Source: mbl.is

Insights:
  • Amgen specializes in translational science and drug development, heavily investing in R&D to advance its pipeline of new medicines through clinical trials and regulatory approvals.
  • Stefánsson and deCode Genetics focus on large-scale population genetics research, using Iceland's unique data to uncover genetic variants linked to diseases and inform personalized medicine and drug development.
  • Amgen concentrates on serious and rare diseases, with a strong emphasis on oncology, inflammation, and integrating advanced molecular and genomic science in therapeutic areas.
  • deCODE emphasizes genetic epidemiology to understand disease risk, genetic architecture, and drug response on a population scale.
Comparison:

| Aspect | Amgen | Kári Stefánsson / deCODE Genetics ||--------------------|-----------------------------|-------------------------------------|| Core mission | Translating biotechnology into patient-focused medicines and care programs | Understanding the genetic basis of diseases through population genetics research || Approach | Drug discovery, development, clinical trials, manufacturing | Population genetics, genetic epidemiology, big data integration || Investment | Multi-billion dollar R&D and manufacturing infrastructure | Focus on genomic data collection and analysis || Focus areas | Serious illnesses, rare diseases, oncology, inflammation | Genetic determinants of common and complex diseases in defined populations || Outcome focus | New medicines, therapies, patient care programs | Genetic insights for personalized medicine and drug discovery || Scale | Global pharmaceutical development and commercialization | Population-level genetic research with far-reaching implications |

  1. Despite Kári Stefánsson's dismissal from deCode Genetics, his impact on global genetic research, particularly in Iceland, remains significant.
  2. As Amgen and Stefánsson's approaches to biomedical science differ in philosophy, their strategies offer a broad spectrum of scientific progress in health-and-wellness, pursuit of targeted drug development by Amgen versus Stefánsson's passion for comprehensive genetic and epidemiological research.
  3. The geneticist's abrupt departure triggered by clashing scientific priorities with Amgen doesn't dent Stefánsson's enthusiasm for science; instead, he remains hopeful about decoding nature's secrets elsewhere in the field.
  4. In California's Amgen headquarters, the clash of perspectives with regards to genetic research led to Stefánsson's dismissal, leaving his comrades, Patrick Sulem and Daníel Guðbjartsson, to regroup and return to Iceland.
  5. Science news continues to buzz with reports on how Amgen's translational science and drug development focus complements Stefánsson's genetic epidemiology work, opening possibilities for advancements in fitness-and-exercise and well-being through the synergy of their contributions.

Read also:

    Related

    Latest